NASDAQ:INVA Innoviva (INVA) Stock Price, News & Analysis → Make This $3 Trade the Instant the Opening Bell Rings (From Monument Traders Alliance) (Ad) Free INVA Stock Alerts $14.56 -0.30 (-2.02%) (As of 03/18/2024 ET) Add Compare Share Share Today's Range$14.55▼$14.9950-Day Range$14.56▼$16.7752-Week Range$10.96▼$16.86Volume864,063 shsAverage Volume709,009 shsMarket Capitalization$920.63 millionP/E Ratio6.68Dividend YieldN/APrice Target$22.50 Stock AnalysisStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSocial MediaSustainabilityStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSocial MediaSustainability Get Innoviva alerts: Email Address Innoviva MarketRank™ Stock AnalysisAnalyst RatingBuy3.00 Rating ScoreUpside/Downside54.5% Upside$22.50 Price TargetShort InterestBearish21.33% of Float Sold ShortDividend StrengthN/ASustainability-0.33Upright™ Environmental ScoreNews Sentiment0.94Based on 2 Articles This WeekInsider TradingN/AProj. Earnings GrowthN/ASee Full Details Hide Full Details Overall MarketRank™New Rank-Based ScoringMarketRank™ is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.3.97 out of 5 starsMedical Sector249th out of 947 stocksPharmaceutical Preparations Industry113th out of 435 stocks 3.5 Analyst's Opinion Consensus RatingInnoviva has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 1 buy rating, no hold ratings, and no sell ratings.Price Target Upside/DownsideAccording to analysts' consensus price target of $22.50, Innoviva has a forecasted upside of 54.5% from its current price of $14.56.Amount of Analyst CoverageInnoviva has received no research coverage in the past 90 days. Previous Next 0.0 Short Interest Percentage of Shares Shorted21.33% of the float of Innoviva has been sold short.Short Interest Ratio / Days to CoverInnoviva has a short interest ratio ("days to cover") of 17.8, which indicates bearish sentiment.Change versus previous monthShort interest in Innoviva has recently increased by 7.85%, indicating that investor sentiment is decreasing significantly. Previous Next 0.0 Dividend Strength Dividend YieldInnoviva does not currently pay a dividend.Dividend GrowthInnoviva does not have a long track record of dividend growth. Previous Next 4.2 Sustainability and ESG Overall ESG (Environmental, Social, and Governance) ScoreInnoviva has received a 60.40% net impact score from Upright. The largest positive contribution comes from its "Physical diseases" impact, which is driven by its "Private equity funds investing in the pharmaceuticals industry" product. See details.Environmental SustainabilityThe Environmental Impact score for Innoviva is -0.33. Previous Next 3.3 News and Social Media Coverage News SentimentInnoviva has a news sentiment score of 0.94. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.64 average news sentiment score of Medical companies.News Coverage This WeekMarketBeat has tracked 2 news articles for Innoviva this week, compared to 1 article on an average week.Search InterestOnly 1 people have searched for INVA on MarketBeat in the last 30 days. This is a decrease of 0% compared to the previous 30 days.MarketBeat Follows1 people have added Innoviva to their MarketBeat watchlist in the last 30 days. Previous Next 1.7 Company Ownership Insider Buying vs. Insider SellingIn the past three months, Innoviva insiders have not sold or bought any company stock.Percentage Held by InsidersOnly 1.40% of the stock of Innoviva is held by insiders.Percentage Held by Institutions99.12% of the stock of Innoviva is held by institutions. High institutional ownership can be a signal of strong market trust in this company. Previous Next 1.3 Earnings and Valuation Price to Earnings Ratio vs. the MarketThe P/E ratio of Innoviva is 6.68, which means that it is trading at a less expensive P/E ratio than the market average P/E ratio of about 152.03.Price to Earnings Ratio vs. SectorThe P/E ratio of Innoviva is 6.68, which means that it is trading at a less expensive P/E ratio than the Medical sector average P/E ratio of about 223.39.Price to Book Value per Share RatioInnoviva has a P/B Ratio of 1.37. P/B Ratios below 3 indicates that a company is reasonably valued with respect to its assets and liabilities. Previous Next See Top Rated MarketRank™ Stocks Here Ad Prosper Trading AcademyDid you make $29,000 two days with AI options trades?What if it was possible to find options trades on autopilot… Using A.I. to find the ones with the highest profit potential… And nearly perfect win rates… You can grab your free copy of my "Ultimate Guide to A.I. Options Trading" by clicking the link below:Click Here To Get Your Free Copy About Innoviva Stock (NASDAQ:INVA)Innoviva, Inc. engages in the development and commercialization of pharmaceutical products in the United States and internationally. The company's products include RELVAR/BREO ELLIPTA, a once-daily combination medicine consisting of a LABA, vilanterol (VI), an inhaled corticosteroid (ICS), and fluticasone furoate; ANORO ELLIPTA, a once-daily medicine combining a long-acting muscarinic antagonist (LAMA) and umeclidinium bromide (UMEC) with a LABA, VI; GIAPREZA (angiotensin II), a vasoconstrictor to increase blood pressure in adults with septic or other distributive shock; XERAVA (eravacycline) for the treatment of complicated intra-abdominal infections in adults; and XACDURO, a beta lactamase inhibitor for the treatment of hospital-acquired bacterial pneumonia and ventilator-associated bacterial pneumonia. Its development pipeline includes zoliflodacin, a late-stage product candidate, a potential single oral dose cure for the treatment of uncomplicated gonorrhea. Innoviva, Inc. has a strategic partnership with Sarissa Capital Management LP. It has long-acting beta2 agonist (LABA) collaboration agreement with Glaxo Group Limited to develop and commercialize once-daily products for the treatment of chronic obstructive pulmonary disease and asthma. The company was formerly known as Theravance, Inc. and changed its name to Innoviva, Inc. in January 2016. Innoviva, Inc. was incorporated in 1996 and is headquartered in Burlingame, California.Read More INVA Stock Price History View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart INVA Stock News HeadlinesMarch 8, 2024 | benzinga.comInsider Decision Unfolding At Innoviva: Pavel Raifeld Exercises OptionsMarch 4, 2024 | msn.comArmata enters $35M credit agreement with InnovivaMarch 19, 2024 | Monument Traders Alliance (Ad)Make This $3 Trade the Instant the Opening Bell RingsSince the birth of Wall Street, one simple rule has remained the same.... Buy stocks that are cheap....When they’re on sale…. And when nobody else is looking…February 29, 2024 | finance.yahoo.comInnoviva Reports Fourth Quarter and Full Year 2023 Financial Results; Highlights Recent Company ProgressFebruary 29, 2024 | businesswire.comInnoviva Reports Fourth Quarter and Full Year 2023 Financial Results; Highlights Recent Company ProgressFebruary 28, 2024 | msn.com10 stocks you can bet on being inflation-proofFebruary 14, 2024 | finance.yahoo.comJim Simons Bolsters Position in Innoviva Inc with Recent AcquisitionFebruary 8, 2024 | morningstar.comInnoviva Inc INVAMarch 19, 2024 | Monument Traders Alliance (Ad)Make This $3 Trade the Instant the Opening Bell RingsSince the birth of Wall Street, one simple rule has remained the same.... Buy stocks that are cheap....When they’re on sale…. And when nobody else is looking…February 6, 2024 | morningstar.comCosmo Pharmaceuticals NV COPNJanuary 25, 2024 | stocknews.com3 Lucrative Biotech Stock Buys for SuccessJanuary 8, 2024 | msn.comChart of the Day: Innoviva - Individual Investor FavoriteDecember 30, 2023 | finance.yahoo.comInnoviva's (NASDAQ:INVA) investors will be pleased with their 29% return over the last three yearsDecember 21, 2023 | uk.finance.yahoo.comInnoviva, Inc. (INVA) stock historical prices & data – Yahoo FinanceDecember 11, 2023 | stocknews.comAnalyzing the Bullish Opportunities of 3 Biotech StocksNovember 27, 2023 | msn.comInnoviva (INVA) Price Target Increased by 7.14% to 15.30November 18, 2023 | finance.yahoo.comInsider Sell Alert: Marianne Zhen Offloads Shares of Innoviva IncNovember 14, 2023 | finance.yahoo.comInnoviva, Inc. (NASDAQ:INVA) Has Fared Decently But Fundamentals Look Uncertain: What Lies Ahead For The Stock?November 3, 2023 | finance.yahoo.comInnoviva Inc (INVA) Reports Q3 2023 Financial Results: Net Income Drops to $82.0 MillionNovember 1, 2023 | finance.yahoo.comPositive Results Announced in Largest Pivotal Phase 3 Trial of a First-in-Class Oral Antibiotic to Treat Uncomplicated GonorrheaNovember 1, 2023 | finance.yahoo.comInnoviva Reports Third Quarter 2023 Financial Results and Highlights Recent Company ProgressOctober 18, 2023 | finance.yahoo.comCalculating The Intrinsic Value Of Innoviva, Inc. (NASDAQ:INVA)October 9, 2023 | seekingalpha.comInnoviva: A Lot Of Moving PartsSeptember 19, 2023 | finance.yahoo.comInnoviva to Participate in the Cantor Global Healthcare ConferenceSeptember 18, 2023 | finance.yahoo.comXACDURO®, The First and Only Antibiotic Developed to Target Acinetobacter, Now Available to Treat Hospital-Acquired Bacterial Pneumonia (HABP) and Ventilator-Associated Bacterial Pneumonia (VABP) in AdultsAugust 25, 2023 | finance.yahoo.comInnoviva Appoints Stephen Basso as Chief Financial OfficerAugust 3, 2023 | finance.yahoo.comInnoviva Reports Second Quarter 2023 Financial Results and Highlights Recent Company ProgressSee More Headlines Receive INVA Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Innoviva and its competitors with MarketBeat's FREE daily newsletter. Email Address Company Calendar Last Earnings2/29/2024Today3/18/2024Next Earnings (Estimated)5/14/2024Fiscal Year End12/31/2024Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry Pharmaceutical preparations Sub-IndustryBiotechnology Current SymbolNASDAQ:INVA Previous SymbolNASDAQ:THRX CUSIP88338T10 CIK1080014 Webwww.inva.com Phone(650) 238-9600Fax650-827-8690Employees112Year Founded1996Price Target and Rating Average Stock Price Target$22.50 High Stock Price Target$22.50 Low Stock Price Target$22.50 Potential Upside/Downside+54.5%Consensus RatingBuy Rating Score (0-4)3.00 Research Coverage1 Analysts Profitability EPS (Most Recent Fiscal Year)$2.18 Trailing P/E Ratio6.68 Forward P/E RatioN/A P/E GrowthN/ANet Income$179.72 million Net Margins57.89% Pretax Margin62.52% Return on Equity30.37% Return on Assets15.70% Debt Debt-to-Equity Ratio0.66 Current Ratio9.03 Quick Ratio7.96 Sales & Book Value Annual Sales$310.46 million Price / Sales2.97 Cash Flow$3.46 per share Price / Cash Flow4.21 Book Value$10.66 per share Price / Book1.37Miscellaneous Outstanding Shares63,230,000Free Float62,342,000Market Cap$920.63 million OptionableOptionable Beta0.57 Social Links Metaverse Stocks And Why You Can't Ignore ThemThinking about investing in Meta, Roblox, or Unity? Click the link to learn what streetwise investors need to know about the metaverse and public markets before making an investment.Get This Free Report Key ExecutivesMr. Pavel Raifeld C.F.A. (Age 40)Chief Executive Officer Comp: $754.67kMr. Stephen Basso M.B.A. (Age 58)Chief Financial Officer Key CompetitorsGeronNASDAQ:GERNMannKindNASDAQ:MNKDOPKO HealthNASDAQ:OPKLexicon PharmaceuticalsNASDAQ:LXRXLigand PharmaceuticalsNASDAQ:LGNDView All CompetitorsInsiders & InstitutionsVanguard Group Inc.Sold 4,994 shares on 3/11/2024Ownership: 10.616%Wellington Management Group LLPBought 120,926 shares on 3/5/2024Ownership: 0.189%Gerber LLCBought 34,300 shares on 3/5/2024Ownership: 0.054%Price T Rowe Associates Inc. MDBought 1,360 shares on 2/16/2024Ownership: 0.077%DZ BANK AG Deutsche Zentral Genossenschafts Bank Frankfurt am MainSold 139,849 shares on 2/16/2024Ownership: 0.016%View All Insider TransactionsView All Institutional Transactions INVA Stock Analysis - Frequently Asked Questions Should I buy or sell Innoviva stock right now? 1 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Innoviva in the last year. There are currently 1 buy rating for the stock. The consensus among Wall Street equities research analysts is that investors should "buy" INVA shares. View INVA analyst ratings or view top-rated stocks. What is Innoviva's stock price target for 2024? 1 brokers have issued 12 month price objectives for Innoviva's shares. Their INVA share price targets range from $22.50 to $22.50. On average, they anticipate the company's stock price to reach $22.50 in the next year. This suggests a possible upside of 54.5% from the stock's current price. View analysts price targets for INVA or view top-rated stocks among Wall Street analysts. How have INVA shares performed in 2024? Innoviva's stock was trading at $16.04 on January 1st, 2024. Since then, INVA stock has decreased by 9.2% and is now trading at $14.56. View the best growth stocks for 2024 here. Are investors shorting Innoviva? Innoviva saw a increase in short interest in February. As of February 29th, there was short interest totaling 13,320,000 shares, an increase of 7.9% from the February 14th total of 12,350,000 shares. Based on an average daily volume of 747,400 shares, the days-to-cover ratio is presently 17.8 days. Approximately 21.3% of the shares of the stock are sold short. View Innoviva's Short Interest. When is Innoviva's next earnings date? The company is scheduled to release its next quarterly earnings announcement on Tuesday, May 14th 2024. View our INVA earnings forecast. How were Innoviva's earnings last quarter? Innoviva, Inc. (NASDAQ:INVA) released its earnings results on Thursday, February, 29th. The biotechnology company reported $0.76 earnings per share (EPS) for the quarter. The biotechnology company earned $85.84 million during the quarter. Innoviva had a net margin of 57.89% and a trailing twelve-month return on equity of 30.37%. What ETFs hold Innoviva's stock? ETFs with the largest weight of Innoviva (NASDAQ:INVA) stock in their portfolio include LeaderShares Activist Leaders ETF (ACTV), ETC 6 Meridian Small Cap Equity ETF (SIXS), Pacer US Small Cap Cash Cows Growth Leaders ETF (CAFG), Invesco S&P SmallCap Health Care ETF (PSCH), SPDR S&P Pharmaceuticals ETF (XPH), Direxion Daily Pharmaceutical & Medical Bull 3X Shares (PILL) and iShares U.S. Pharmaceuticals ETF (IHE).Harbor Health Care ETF (MEDI). What other stocks do shareholders of Innoviva own? Based on aggregate information from My MarketBeat watchlists, some companies that other Innoviva investors own include Inovio Pharmaceuticals (INO), Gilead Sciences (GILD), Exelixis (EXEL), Micron Technology (MU), Advanced Micro Devices (AMD), Pfizer (PFE), Vertex Pharmaceuticals (VRTX), NVIDIA (NVDA), OPKO Health (OPK) and Sorrento Therapeutics (SRNE). Who are Innoviva's major shareholders? Innoviva's stock is owned by many different retail and institutional investors. Top institutional shareholders include Vanguard Group Inc. (10.47%), Vanguard Group Inc. (10.62%), Dimensional Fund Advisors LP (7.05%), Westfield Capital Management Co. LP (4.08%), Pacer Advisors Inc. (2.70%) and Charles Schwab Investment Management Inc. (1.46%). Insiders that own company stock include Alexander J Denner, George Bickerstaff, Innoviva, Inc, Marianne Zhen, Pavel Raifeld and Plc Glaxosmithkline. View institutional ownership trends. How do I buy shares of Innoviva? Shares of INVA stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Compare Top Brokerages Here. This page (NASDAQ:INVA) was last updated on 3/19/2024 by MarketBeat.com Staff From Our Partners8,788% Return Predicted For THIS Crypto (already up 40% in 6 months)Paradigm PressCentral Bank Gold Heist In ProgressColonial MetalsLike Tiny Crypto Retirement FundsCrypto 101 MediaThe AI Bottleneck No One is Talking AboutThe Bull ReportMake This $3 Trade the Instant the Opening Bell RingsMonument Traders AllianceSHOCKING Footage From Tesla Gigafactory In Austin, TexasInvestorPlaceThe world’s greatest investmentPorter & CompanyStock-Picking AI Predicts #1 Stock of 2024Altimetry Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Innoviva, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Your Password: or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Choose a Password: Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.